These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25260883)

  • 1. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
    Liu L; Guo J; Yu L; Cai J; Gui T; Tang H; Song L; Wang J; Han F; Yang C; Chen C; Marks A; Wang Z
    Tumour Biol; 2014 Dec; 35(12):12619-26. PubMed ID: 25260883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
    Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
    Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
    Semaan A; Qazi AM; Seward S; Chamala S; Bryant CS; Kumar S; Morris R; Steffes CP; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
    Pharm Res; 2011 Dec; 28(12):3079-90. PubMed ID: 21818714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Sun J; Cai X; Yung MM; Zhou W; Li J; Zhang Y; Li Z; Liu SS; Cheung ANY; Ngan HYS; Li Y; Dai Z; Kai Y; Tzatsos A; Peng W; Chan DW; Zhu W
    Oncogene; 2019 Jan; 38(4):564-580. PubMed ID: 30166592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
    Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
    Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
    Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
    Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.